Thomas J. Fahey
YOU?
Author Swipe
View article: Developing a Predictive Model for Metastatic Potential in Pancreatic Neuroendocrine Tumor
Developing a Predictive Model for Metastatic Potential in Pancreatic Neuroendocrine Tumor Open
Context Pancreatic neuroendocrine tumors (PNETs) exhibit a wide range of behavior from localized disease to aggressive metastasis. A comprehensive transcriptomic profile capable of differentiating between these phenotypes remains elusive. …
View article: 31P Surgical and chemotherapeutic strategies for stage IV pancreatic neuroendocrine carcinoma according to the latest WHO classification
31P Surgical and chemotherapeutic strategies for stage IV pancreatic neuroendocrine carcinoma according to the latest WHO classification Open
Chemotherapy is considered the primary treatment for stage IV pancreatic neuroendocrine carcinoma (pNEC). However, the optimal management of metastatic pNEC as defined by the updated WHO classification (2022) has not been adequately explor…
View article: OR08-06 Adjuvant Radiation Therapy Is Not Associated With A Survival Benefit After R0 Resection In Non-Metastatic Adrenocortical Carcinoma
OR08-06 Adjuvant Radiation Therapy Is Not Associated With A Survival Benefit After R0 Resection In Non-Metastatic Adrenocortical Carcinoma Open
Disclosure: Y.J. Lee-Saxton: None. C.E. Egan: None. T.E. Marshall: None. A. Tumati: None. T. Beninato: None. R. Zarnegar: None. T.J. Fahey: None. B.M. Finnerty: None. Introduction: The benefit of adjuvant radiation therapy (RT) in adrenoco…
View article: Data from Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAF<sup>V600E</sup> Positive Thyroid Carcinoma
Data from Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAF<sup>V600E</sup> Positive Thyroid Carcinoma Open
A subset of thyroid cancers, recurrent differentiated thyroid cancers and anaplastic thyroid cancer (ATC), are difficult to treat by thyroidectomy and systemic therapy. A common mutation in thyroid cancer, BRAFV600E, has targetable treatme…
View article: Supplementary Tables 1-5 from Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAF<sup>V600E</sup> Positive Thyroid Carcinoma
Supplementary Tables 1-5 from Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAF<sup>V600E</sup> Positive Thyroid Carcinoma Open
Supplementary Table 1. Gene expression changes in 8505C after vemurafenib treatment.Supplementary Table 2. Gene expression changes in WRO after vemurafenib treatment.Supplementary Table 3. Gene expression changes in 8505C -Vem-Res 1 relati…
View article: Supplementary Tables 1-5 from Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAF<sup>V600E</sup> Positive Thyroid Carcinoma
Supplementary Tables 1-5 from Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAF<sup>V600E</sup> Positive Thyroid Carcinoma Open
Supplementary Table 1. Gene expression changes in 8505C after vemurafenib treatment.Supplementary Table 2. Gene expression changes in WRO after vemurafenib treatment.Supplementary Table 3. Gene expression changes in 8505C -Vem-Res 1 relati…
View article: Supplementary Figures 1-7 from Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAF<sup>V600E</sup> Positive Thyroid Carcinoma
Supplementary Figures 1-7 from Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAF<sup>V600E</sup> Positive Thyroid Carcinoma Open
S1. BRAFV600E mutation identified in thyroid cancer cell lines analyzed by RNA-seq.S2. STR analysis in thyroid cancer cell lines used in this study.S3. Gene expression of thyroid-specific genes in thyroid cancer cell lines analyzed by RNA-…
View article: Data from Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAF<sup>V600E</sup> Positive Thyroid Carcinoma
Data from Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAF<sup>V600E</sup> Positive Thyroid Carcinoma Open
A subset of thyroid cancers, recurrent differentiated thyroid cancers and anaplastic thyroid cancer (ATC), are difficult to treat by thyroidectomy and systemic therapy. A common mutation in thyroid cancer, BRAFV600E, has targetable treatme…
View article: Supplementary Figures 1-7 from Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAF<sup>V600E</sup> Positive Thyroid Carcinoma
Supplementary Figures 1-7 from Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAF<sup>V600E</sup> Positive Thyroid Carcinoma Open
S1. BRAFV600E mutation identified in thyroid cancer cell lines analyzed by RNA-seq.S2. STR analysis in thyroid cancer cell lines used in this study.S3. Gene expression of thyroid-specific genes in thyroid cancer cell lines analyzed by RNA-…
View article: Supplementary Figures 1-7 from Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAF<sup>V600E</sup> Positive Thyroid Carcinoma
Supplementary Figures 1-7 from Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAF<sup>V600E</sup> Positive Thyroid Carcinoma Open
S1. BRAFV600E mutation identified in thyroid cancer cell lines analyzed by RNA-seq.S2. STR analysis in thyroid cancer cell lines used in this study.S3. Gene expression of thyroid-specific genes in thyroid cancer cell lines analyzed by RNA-…
View article: Supplementary Tables 1-5 from Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAF<sup>V600E</sup> Positive Thyroid Carcinoma
Supplementary Tables 1-5 from Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAF<sup>V600E</sup> Positive Thyroid Carcinoma Open
Supplementary Table 1. Gene expression changes in 8505C after vemurafenib treatment.Supplementary Table 2. Gene expression changes in WRO after vemurafenib treatment.Supplementary Table 3. Gene expression changes in 8505C -Vem-Res 1 relati…
View article: Data from Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAF<sup>V600E</sup> Positive Thyroid Carcinoma
Data from Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAF<sup>V600E</sup> Positive Thyroid Carcinoma Open
A subset of thyroid cancers, recurrent differentiated thyroid cancers and anaplastic thyroid cancer (ATC), are difficult to treat by thyroidectomy and systemic therapy. A common mutation in thyroid cancer, BRAFV600E, has targetable treatme…
View article: Supplementary Tables 1-5 from Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAF<sup>V600E</sup> Positive Thyroid Carcinoma
Supplementary Tables 1-5 from Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAF<sup>V600E</sup> Positive Thyroid Carcinoma Open
Supplementary Table 1. Gene expression changes in 8505C after vemurafenib treatment.Supplementary Table 2. Gene expression changes in WRO after vemurafenib treatment.Supplementary Table 3. Gene expression changes in 8505C -Vem-Res 1 relati…
View article: Supplementary Figures 1-7 from Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAF<sup>V600E</sup> Positive Thyroid Carcinoma
Supplementary Figures 1-7 from Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAF<sup>V600E</sup> Positive Thyroid Carcinoma Open
S1. BRAFV600E mutation identified in thyroid cancer cell lines analyzed by RNA-seq.S2. STR analysis in thyroid cancer cell lines used in this study.S3. Gene expression of thyroid-specific genes in thyroid cancer cell lines analyzed by RNA-…
View article: Supplementary Table 2 from A Panel of Four miRNAs Accurately Differentiates Malignant from Benign Indeterminate Thyroid Lesions on Fine Needle Aspiration
Supplementary Table 2 from A Panel of Four miRNAs Accurately Differentiates Malignant from Benign Indeterminate Thyroid Lesions on Fine Needle Aspiration Open
PDF file - 78K
View article: Data from CAR T Therapy Targeting ICAM-1 Eliminates Advanced Human Thyroid Tumors
Data from CAR T Therapy Targeting ICAM-1 Eliminates Advanced Human Thyroid Tumors Open
Purpose: Poorly differentiated thyroid cancer and anaplastic thyroid cancer (ATC) are rare yet lethal malignancies with limited treatment options. Many malignant tumors, including papillary thyroid cancer (PTC) and ATC, are associated with…
View article: Supplementary Table 1 from PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer
Supplementary Table 1 from PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer Open
Summary of donor T cells used for CAR T cell generation and response to anti-PD1 antibody treatment in vitro and in vivo.
View article: Supplementary Table 1 from PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer
Supplementary Table 1 from PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer Open
Summary of donor T cells used for CAR T cell generation and response to anti-PD1 antibody treatment in vitro and in vivo.
View article: Supplementary Table 1 from A Panel of Four miRNAs Accurately Differentiates Malignant from Benign Indeterminate Thyroid Lesions on Fine Needle Aspiration
Supplementary Table 1 from A Panel of Four miRNAs Accurately Differentiates Malignant from Benign Indeterminate Thyroid Lesions on Fine Needle Aspiration Open
PDF file - 76K
View article: Data from CAR T Therapy Targeting ICAM-1 Eliminates Advanced Human Thyroid Tumors
Data from CAR T Therapy Targeting ICAM-1 Eliminates Advanced Human Thyroid Tumors Open
Purpose: Poorly differentiated thyroid cancer and anaplastic thyroid cancer (ATC) are rare yet lethal malignancies with limited treatment options. Many malignant tumors, including papillary thyroid cancer (PTC) and ATC, are associated with…
View article: Supplementary Figure 2 from PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer
Supplementary Figure 2 from PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer Open
Characteristics of each donor leukopak used in in vivo study.
View article: Data from A Panel of Four miRNAs Accurately Differentiates Malignant from Benign Indeterminate Thyroid Lesions on Fine Needle Aspiration
Data from A Panel of Four miRNAs Accurately Differentiates Malignant from Benign Indeterminate Thyroid Lesions on Fine Needle Aspiration Open
Purpose: Indeterminate thyroid lesions on fine needle aspiration (FNA) harbor malignancy in about 25% of cases. Hemi- or total thyroidectomy has, therefore, been routinely advocated for definitive diagnosis. In this study, we analyzed miRN…
View article: Supplementary Figure 1 from PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer
Supplementary Figure 1 from PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer Open
Expression of ICAM1 and PD-L1 in anaplastic thyroid tumor cell lines.
View article: Supplementary Figure 3 from PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer
Supplementary Figure 3 from PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer Open
PD1 inhibition enhances survival benefit of CAR T treatment in KHM-5M xenografts.
View article: Data from PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer
Data from PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer Open
Purpose:Advanced thyroid cancers, including poorly differentiated and anaplastic thyroid cancer (ATC), are lethal malignancies with limited treatment options. The majority of patients with ATC have responded poorly to programmed death 1 (P…
View article: Supplementary Table 1 from A Panel of Four miRNAs Accurately Differentiates Malignant from Benign Indeterminate Thyroid Lesions on Fine Needle Aspiration
Supplementary Table 1 from A Panel of Four miRNAs Accurately Differentiates Malignant from Benign Indeterminate Thyroid Lesions on Fine Needle Aspiration Open
PDF file - 76K
View article: Data from PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer
Data from PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer Open
Purpose:Advanced thyroid cancers, including poorly differentiated and anaplastic thyroid cancer (ATC), are lethal malignancies with limited treatment options. The majority of patients with ATC have responded poorly to programmed death 1 (P…
View article: Data from A Panel of Four miRNAs Accurately Differentiates Malignant from Benign Indeterminate Thyroid Lesions on Fine Needle Aspiration
Data from A Panel of Four miRNAs Accurately Differentiates Malignant from Benign Indeterminate Thyroid Lesions on Fine Needle Aspiration Open
Purpose: Indeterminate thyroid lesions on fine needle aspiration (FNA) harbor malignancy in about 25% of cases. Hemi- or total thyroidectomy has, therefore, been routinely advocated for definitive diagnosis. In this study, we analyzed miRN…
View article: Supplementary Figure 1 from PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer
Supplementary Figure 1 from PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer Open
Expression of ICAM1 and PD-L1 in anaplastic thyroid tumor cell lines.